Strides Pharma sells majority stake in arm Pivot Path for ₹100 cr

▤ Summary

Strides Pharma is selling a majority stake in Pivot Path for ₹100 crore to a consortium led by Ascent Capital, while retaining a 19.95% stake. The deal also includes a ₹50 crore primary infusion into Pivot Path to fund its next growth phase. Strides says the transaction unlocks value and lets Pivot Path operate more independently. Pivot Path’s business centers on life sciences consulting, digital transformation, quality and compliance, and technology-enabled operational services for pharma customers.

▦ Linked Companies